33 results about "Sterane" patented technology

An optimal preparation and analytic method for the extraction of Antrodia cinnamomea is disclosed. The important parameters for the extraction efficiency of the extract are analyzed using mathematic and statistical experimental designs, and the extract of A. cinnamomea and its particular triterpenoid compounds are quantified and identified using the quantitative NMR and HPLC-tandem MS. Whether the ergostane and lanostane triterpenoid compounds are contained in one drug, health food or other products and the total amounts and individual amounts therein can be analyzed, determined or quantified using the techniques disclosed herein.

The present invention relates to a method for analyzing sterane-based compounds in a petroleum geological sample. According to the method, organic matters in a rock core sample are extracted with an organic solvent, and the extracted supernatant is directly analyzed through atmospheric pressure photoionization high resolution mass spectrometry (APPI FT-ICR MS). According to the present invention,with the method, the sample consumption is low, the sample preparation process is simple, the sample extraction time is short, and the extract can be directly subjected to atmospheric pressure photoionization high resolution mass spectrometry analysis without concentration and separation so as to avoid the compound loss caused during the separation; and the atmospheric pressure photoionization high resolution mass spectrometry analysis process is accurate and rapid, the sterane-based compound carbon number distribution range detected by the high resolution mass spectrometry has high reliability and high accuracy compared to the GC-MS results, and the method for analyzing the sterane-based compounds in the petroleum geological sample is expanded.

The invention discloses a chalcone derivative containing an allyl structure and its application. The invention synthesizes 39 new allyl-post-steranes based on Licochalcone A and E as promolecules. As a PTP1B inhibitor, it may improve the common treatment of type 2 diabetes. Most of the synthetic compounds showed potent inhibition of PTP1B.

The invention relates to a molecular sieve separating and preparing method for sterane and diahopane. 60mg of crude oil or rock extracts are prepared, 6g of solica, the particle diameter of which is 40 micrometers, is used for filling columns, and 15ml of n-hexane is used for preparing saturated hydrocarbon in a leaching manner; ZSM molecular sieve with the weight about 100 times the weight of the saturated hydrocarbon is used for filling columns and 20ml of isooctane is used for preparing cyclic hydrocarbon in the leaching manner; 10X molecular sieve with the weight about 300 times the weight of the cyclic hydrocarbon is used for filling columns, and after 30 minutes, 80ml of n-pentane is used for preparing fractions; the solvent of fractions is recovered and volatilized, the fractions are then weighted, 10X molecular sieve with the weight about 200 times the weight of the fractions is used for filling columns and after 30 minutes 10ml is used for preparing sterane in the leaching manner; the filling materials in the third step is dried by the nitrogen, which are then extracted by the isooctane for 12 hours to get diahopane. The separation effect is good after the mass detection of a chromatograph, which is similar to the effect of the separation spectrogram exhibited in foreign countries and the operation of the enriching and separating method of diahopane is simple.

The invention discloses a method for efficient separation and recycling of 5,10-alpha epoxy isomer in telapristone synthesis. A 5,10-alpha epoxide is a key intermediate in a telapristone synthesis process, and preparation of a high-purity 5,10-alpha epoxy isomer is the key in control of a whole quality system. The 5,10-alpha isomer is efficiently separated by means of solvent pulping for the first time, the content reaches 99%, and the yield is up to 65%. More significantly, a mixture of two epoxy isomers in mother solution after separation of the 5,10-alpha epoxy isomer can be subjected to reduction and elimination reaction to return to a raw material 17beta-cyano-17alpha-trimethylsiloxy-13beta-methyl sterane-5,9-diene-3,3-(ethylenedioxy). The method is remarkable in improvement of raw material utilization efficiency and has a large-scale application prospect.

The invention discloses an androstane-3β-hydroxy-17-ketone-6α-boronic acid obtained by separating androstane-3β-hydroxy-17-ketone-6α-boronic acid from a chemical reduction reaction solid waste of androst-5-ene-17-ketone through esterification, oxidation and sulfonic acid. A method for preparing 3β-acetoxyandrost-5-ene-17-ketone by esterification and elimination four-step reaction. The method of the invention can effectively recycle and reuse the steroid solid waste, the synthesis method is efficient, the reaction conditions are mild, the environmental pollution is reduced, and the cost of related products is correspondingly reduced.

The present invention relates to the new process of synthesizing furasteroid saponin and its derivative chemically with C27 helical sterane type sapogenin and various kinds of saccharide as material. The synthesis process includes the following steps: 1. synthesizing completely protected C27 helical steroid saponin through the reaction of C27 helical sterane type sapogenin and acyl radical, alkyl radical or silicon radical protected glycosyl donor; 2. reaction of completely protected helical steroid saponin and oxidant to obtain oxidized product; 3. reaction of oxidized helical steroid saponin and oxyphilic reagent to produce place 26 halogenated saponin derivative; 4. nucleophilic substitution reaction of nucleophilic reagent and the halogenated product to introduce XR3 radical; 5. reducing the place 16 carbonyl radical in saponin selectively with reductant; and 6. eliminating all the protecting radicals to obtain furasteroid saponin and its analog.

The invention discloses an application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy in preparation of medicaments for preventing and / or treating enterovirus 71 infection. The invention confirms that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good antiviral effect in in-vitro enterovirus 71 (EV 71) infection cell tests. Meanwhile, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxyhas certain killing effect on enterovirus 71 (EV 71), can prevent enterovirus 71 (EV 71) infection, has good treating effect on enterovirus 71 (EV 71) infected cells, has good inhibition effect on viral replication, and has more significant effect than a positive control medicament of ribavirin. In addition, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good inhibition effect on inflammation responses caused by enterovirus 71 (EV 71), which reveals that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has the prospect of being developed into anti-enterovirus 71 (EV 71) medicaments.